Relapsed/Refractory Multiple Myeloma — Microlearning Activity 2 with Dr Sagar Lonial: ASH 2025 Review

Research To Practice | Oncology Videos · Feb 13, 2026 · 17m

Featuring an interview with Dr Sagar Lonial, including the following topics:

Phase 3 randomized study evaluating teclistamab and daratumumab versus investigator's choice of daratumumab and dexamethasone with either pomalidomide or bortezomib for patients with relapsed/refractory (R/R) multiple myeloma (MM) (0:00)

Management of belantamab mafodotin-associated ocular events with dose modifications guided by standard assessments (3:15)

Belantamab mafodotin in combination with bortezomib, lenalidomide and dexamethasone for transplant-ineligible patients with newly diagnosed MM (8:00)

Other…